Brokers Set Expectations for Centessa Pharmaceuticals plc’s Q3 2024 Earnings (NASDAQ:CNTA)

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – B. Riley issued their Q3 2024 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued on Wednesday, September 18th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.44) per share for the quarter. B. Riley currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.61) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at ($2.23) EPS.

CNTA has been the topic of a number of other research reports. BMO Capital Markets raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Jefferies Financial Group lifted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $11.00 to $26.00 in a research report on Thursday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.17.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.58 on Monday. The stock’s 50-day simple moving average is $12.41 and its 200-day simple moving average is $10.67. The firm has a market capitalization of $1.67 billion, a PE ratio of -11.68 and a beta of 1.44. Centessa Pharmaceuticals has a fifty-two week low of $5.15 and a fifty-two week high of $17.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CNTA. Jump Financial LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. Trexquant Investment LP acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $114,000. Franklin Resources Inc. increased its position in shares of Centessa Pharmaceuticals by 34.1% in the fourth quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock valued at $8,882,000 after buying an additional 283,469 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in shares of Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after buying an additional 43,539 shares during the last quarter. Finally, Octagon Capital Advisors LP boosted its position in shares of Centessa Pharmaceuticals by 333.2% in the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after buying an additional 1,584,500 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Saurabh Saha sold 4,169 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider now owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. The disclosure for this sale can be found here. Over the last three months, insiders sold 271,873 shares of company stock valued at $4,381,150. Insiders own 11.59% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.